Latest Intelligence on Immunology and Inflammation in Switzerland

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: Piramed acquisition strengthens its oncology and I&I portfolio

Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.

Published By Datamonitor
15 Apr 2008
CommentWire
CommentWire

Roche/Chugai: gather more positive data for Actemra

The latest Phase III study results for Actemra confirm previous findings that the drug is a safe and effective biologic therapy for rheumatoid arthritis sufferers. In particular, Actemra will be a therapy for niche rheumatoid arthritis patients who do not adequately respond to anti-TNF or traditional disease-modifying drugs, further strengthening the immunology franchise of Roche and Chugai.

Published By Datamonitor
12 Jul 2007
CommentWire
CommentWire

Novartis: the COX-II story so far

Before the FDA asked for additional clinical data, Novartis' [NVS] Prexige was set to be the sixth brand to enter the COX-II market, which already contains Pfizer's [PFE] Celebrex (celecoxib) and Merck's [MRK] Vioxx (rofecoxib). As one of the few potential blockbusters Novartis has in its pipeline, the drug's approval is extremely important for its continuing financial health.

Published By Datamonitor
14 Oct 2003
CommentWire
CommentWire

Novartis: Prexige wins EU approval for osteoarthritis

Following its EU approval, Novartis will look to launch Prexige in the EU during 2007. Despite safety fears over the COX-2 class, there will be a market for Prexige in osteoarthritis as the drug enjoys a similar CV safety profile to Pfizer's Celebrex. Prexige is not expected to reach blockbuster status, but will compete well against Celebrex and Merck's Arcoxia in the five major EU markets.

Published By Datamonitor
09 Nov 2006
CommentWire
CommentWire

Novartis: Prexige proves a pain for Pharmacia

New trial results suggest that Novartis' 400mg Prexige is superior to 200mg Celebrex at providing pain relief for osteoarthritis patients. However, further studies will be needed to consider like-for-like tests and cardiovascular side effects. The results of these will be critical to Prexige's positioning in the extremely competitive pain relief market.

Published By Datamonitor
04 Oct 2002
CommentWire
CommentWire

Novartis: bisphosphonate study should boost Zometa sales

A meta-analysis of bisphosphonate studies found that the drugs can lower skeletal morbidity in patients with metastatic disease. With Novartis' [NVS] Zometa recently gaining a sNDA for patients with bone metastases from advanced malignancies and this class of adjunct therapy becoming increasingly used, Zometa should be blockbuster by the end of 2003.

Published By Datamonitor
01 Sep 2003
Expert View
Expert View

Novartis's novel bronchodilator paves way for potent COPD combinations

Novartis has unveiled promising Phase II data for its once-daily bronchodilator, indacaterol (QAB-149). With a long duration of action, rapid onset of action and clean side effects profile, the drug could provide a new standard for bronchodilator therapy in patients with asthma and chronic obstructive pulmonary disease (COPD).

Published By Datamonitor
09 Jun 2005
CommentWire
CommentWire

Basilea Pharmaceutica: alitretinoin could be safer alternative

Independent Swiss pharmaceutical company Basilea has announced that its dermatology drug alitretinoin has shown positive results in a second phase III clinical trial for the treatment of severe chronic hand dermatitis. Based on these results, alitretinoin could fill an important unmet need for a safer therapy in this indication.

Published By Datamonitor
27 Apr 2007

« | 1 | » »|

No help is available.